REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $272,850.00 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) CEO Kenneth T. Mills sold 15,000 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.19, for a total value of $272,850.00. Following the transaction, the chief executive officer now directly owns 408,035 shares of the company’s stock, valued at $7,422,156.65. The sale was disclosed in a filing with the SEC, which is available at this link.

REGENXBIO Stock Performance

REGENXBIO stock opened at $16.11 on Friday. The stock has a fifty day moving average of $20.03 and a two-hundred day moving average of $17.84. The company has a market capitalization of $790.03 million, a price-to-earnings ratio of -2.67 and a beta of 1.29. REGENXBIO Inc. has a fifty-two week low of $11.83 and a fifty-two week high of $28.80.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.16). REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. The company had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $34.01 million. During the same period last year, the business earned ($1.38) earnings per share. The company’s revenue for the quarter was down 28.8% compared to the same quarter last year. On average, analysts forecast that REGENXBIO Inc. will post -3.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. SVB Leerink raised REGENXBIO from a “market perform” rating to an “outperform” rating and set a $37.00 target price for the company in a research note on Wednesday, March 6th. Chardan Capital reissued a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research note on Thursday, March 7th. Barclays increased their target price on REGENXBIO from $45.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. Leerink Partnrs raised REGENXBIO from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 6th. Finally, Raymond James reissued an “outperform” rating and set a $45.00 target price on shares of REGENXBIO in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.45.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its position in REGENXBIO by 73.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 746 shares during the period. Captrust Financial Advisors increased its position in shares of REGENXBIO by 742.1% during the first quarter. Captrust Financial Advisors now owns 960 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 846 shares during the last quarter. Royal Bank of Canada increased its holdings in REGENXBIO by 189.8% in the third quarter. Royal Bank of Canada now owns 1,397 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 915 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in REGENXBIO in the fourth quarter valued at about $38,000. Finally, Point72 Middle East FZE bought a new stake in REGENXBIO in the fourth quarter valued at about $52,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.